Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is a prospective, randomized, double-blinded, controlled, clinical trial that evaluates the efficacy of using high potency homeopathic Arnica montana (SinEcch™) during the perioperative period for decreasing swelling and pain after extraction of partial or full/complete bony impacted third molars. The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill).
Our study aims to look at the efficacy of homeopathic Arnica montana (SinEcch™) in reducing postoperative edema and pain. Pain will be measured using the visual analog scale (VAS). Swelling will be measured using a 3D imaging system. This is the first study using the 3D imaging system that looks at the effect of homeopathic Arnica montana in reducing facial swelling following the surgical removal of impacted third molars. Although SinEcch is marketed mainly for management of postoperative swelling and bruising, Arnica Montana has been used for managing the sequelae of postoperative inflammation including pain so one of the secondary outcome measure for this study is to measure the efficacy of SinEcch in management of post-operative pain.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Study Group | Experimental | The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. |
|
| Control Group | Placebo Comparator | The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SinEcch | Drug | The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in Postoperative Facial Swelling From Baseline to Day 3 | Primary outcome is the change in postoperative facial swelling volume as measured by the 3dMD™ system | Baseline and Day 3 |
| Change in Postoperative Facial Swelling From Day 3 to Day 5 | Primary outcome is the change in postoperative facial swelling volume as measured by the 3dMD™ system | Day 3 and Day 5 |
| Change in Postoperative Facial Swelling From Baseline to Day 5 | Primary outcome is the change in postoperative facial swelling volume as measured by the 3dMD™ system | Baseline and Day 5 |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Post Operative Pain From Baseline to Day 3 | Change in postoperative pain as measured by 0-100 mm Visual Analog Scale, from baseline to post-operative Day 3, and from baseline to post-operative Day 5 (0 being the least pain, 100 being the most pain) | Baseline and Day 3 |
| Change in Post Operative Pain From Baseline to Day 5 |
Not provided
Inclusion Criteria:
Subjects of either sex and of any race from the ages of 18 to 40 years.
Subjects for whom a decision has been made to extract 4 third molars, and who have at least 2 of third molar teeth classified as full or partially bony impacted in the mandible, and they will be evaluated to have at least 2 of third molar teeth classified as erupted or impacted (full or partially bony) in the maxilla under local anesthesia alone, local anesthesia and sedation, or local anesthesia and general anesthesia, all in an outpatient setting.
Subjects must be physically able to tolerate conventional surgical procedures (ASA I/II).
Subjects must agree to follow the study protocol as shown by signing the informed consent form.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Tufts University School of Dental Medicine Department of Oral and Maxillofacial Surgery | Boston | Massachusetts | 02111 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Study Group | The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. SinEcch: The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. |
| FG001 | Control Group | The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill). Placebo: The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill). |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Study Group | The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. SinEcch: The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Postoperative Facial Swelling From Baseline to Day 3 | Primary outcome is the change in postoperative facial swelling volume as measured by the 3dMD™ system | Posted | Mean | Standard Deviation | cm^2 | Baseline and Day 3 |
|
5 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Study Group | The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. SinEcch: The study group will be comprised of subjects who will receive homeopathic Arnica montana (SinEcch™) for perioperative management of edema and pain. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Principal Investigatort | Tufts University School of Dental Medicine | (617) 636-6515 | dentalresearchadministration@tufts.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Jan 1, 2022 | Aug 4, 2025 | Prot_SAP_002.pdf |
| ICF | No | No | Yes | Informed Consent Form | Jan 18, 2022 | Dec 16, 2025 | ICF_004.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000712347 | Arnicae flos extract |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To decrease bias, this study will be double blinded by blinding information about the specific group from the subject and the investigators. The study medication and matching placebo (sugar pill) will be blinded and packaged in blister cards provided by the Sponsor.
|
| Placebo | Other | The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill). |
|
Change in postoperative pain as measured by 0-100 mm Visual Analog Scale, from baseline to post-operative Day 3, and from baseline to post-operative Day 5 (0 being the least pain, 100 being the most pain) |
| Baseline and Day 5 |
| Control Group |
The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill). Placebo: The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill). |
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Inter-Quartile Range | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| BASELINE Postoperative Swelling | Mean | Standard Deviation | Cm^2 |
|
| BASELINE PAIN | This represents pain that the participant would indicate, through units on a scale, as a way to reflect the level of pain they are in immediately following their surgery, before any study intervention begins. | Mean | Standard Deviation | units on a scale |
|
|
|
| Primary | Change in Postoperative Facial Swelling From Day 3 to Day 5 | Primary outcome is the change in postoperative facial swelling volume as measured by the 3dMD™ system | three subjects did not complete the day 5 visit and thus, data was only analyzed for 50 subjects instead of 53. | Posted | Mean | Standard Deviation | cm^2 | Day 3 and Day 5 |
|
|
|
| Primary | Change in Postoperative Facial Swelling From Baseline to Day 5 | Primary outcome is the change in postoperative facial swelling volume as measured by the 3dMD™ system | three subjects did not complete the day 5 visit and thus, data was only analyzed for 50 subjects instead of 53. | Posted | Mean | Standard Deviation | cm^2 | Baseline and Day 5 |
|
|
|
| Secondary | Change in Post Operative Pain From Baseline to Day 3 | Change in postoperative pain as measured by 0-100 mm Visual Analog Scale, from baseline to post-operative Day 3, and from baseline to post-operative Day 5 (0 being the least pain, 100 being the most pain) | Posted | Mean | Standard Deviation | score on a scale | Baseline and Day 3 |
|
|
|
| Secondary | Change in Post Operative Pain From Baseline to Day 5 | Change in postoperative pain as measured by 0-100 mm Visual Analog Scale, from baseline to post-operative Day 3, and from baseline to post-operative Day 5 (0 being the least pain, 100 being the most pain) | three subjects did not complete the day 5 visit and thus, data was only analyzed for 50 subjects instead of 53. | Posted | Mean | Standard Deviation | score on a scale | Baseline and Day 5 |
|
|
|
| 0 |
| 27 |
| 0 |
| 27 |
| 0 |
| 27 |
| EG001 | Control Group | The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill). Placebo: The control group will be comprised of subjects who will receive matching SinEcch™ placebo (sugar pill). | 0 | 26 | 0 | 26 | 0 | 26 |
Not provided